Paper Review Records
All Paper Review Records
10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
79
days
Helicase-primase inhibitors as next-generation anti-HSV agents: from current clinical status to structure–activity relationships and patent coverage
AuthorsChristian Gege; Gerald Kleymann
Affiliations1. Innovative Molecules GmbH
140
days
T-type calcium channel blockers: a review of recent advances (2018–2025)
AuthorsYasinalli Tamboli; Laurent Ferron; Gerald W. Zamponi
Affiliations1. King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs (MNGH); 2. University of Calgary
76
days
A patent review of mutant-selective PI3Kα inhibitors for the treatment of different cancers (2021–2025)
AuthorsHaixiang Qi; Jiayang Wen; Heng Xu
Affiliations1. Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College
74
days
A patent perspective of RSK inhibitors to treat cancer (2020-present)
AuthorsAviv Preminger; Deborah A. Lannigan
Affiliations1. Vanderbilt University; 2. Vanderbilt University Medical Center
90
days
AKR1C3 inhibitors and exploiters for the treatment and therapeutic monitoring of cancer: a patent review (2020–present)
AuthorsAlfie M. Case; Melanie M. Smith; Cole A. Mack; Paul C. Trippier
Affiliations1. University of Nebraska Medical Center
110
days
Autotaxin inhibitors: an updated patent review (2021-present)
AuthorsXiujian Wei; Chengjing Zhao; Zhi Cao; Zehui Tan; Xin Zhai
Affiliations1. Shenyang Pharmaceutical University
111
days
Recent patent landscape of ASK1 inhibitors: spotlight on 2-(1-isopropyl-4H-1,2,4-triazole-3-yl) pyridine as a privileged scaffold
AuthorsYash Kumar Gaur; Divyanshi Thakur; Shivam Nag; Kalicharan Sharma
Affiliations1. ISF College of Pharmacy; 2. Graphic Era Hill University
74
days
SLIT2 and ROBO-axis inhibitors for the treatment of cancer: a patent review (2020–2026)
AuthorsMahmoud Khatib Al-Ruweidi; Moustafa T. Gabr
Affiliations1. Qatar University; 2. Weill Cornell Medicine
100
days
An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020–present)
AuthorsMennatallah Abdallah; Parthiena M. Keddis; Trevina M. Keddis; Dalia S. El-Gamil; Ashraf H. Abadi; Isao Kii; Matthias Engel; Mohammad Abdel-Halim
Affiliations1. German University in Cairo; 2. Ahram Canadian University; 3. Shinshu University; 4. Saarland University
149
days
A patent review of GPR84 receptor antagonists (2020–present)
AuthorsTianyu Mi; Jiawen Yin; Linhai Chen; Fajun Nan
Affiliations1. Jiangxi University of Chinese Medicine; 2. Bohai Rim Advanced Research Institute for Drug Discovery; 3. Chinese Academy of Sciences
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days